iShares U.S. Pharmaceuticals ETF (IHE)
| Assets | $1.00B |
| Expense Ratio | 0.38% |
| PE Ratio | 21.41 |
| Shares Out | 11.50M |
| Dividend (ttm) | $1.49 |
| Dividend Yield | 1.72% |
| Ex-Dividend Date | Mar 17, 2026 |
| Payout Frequency | Quarterly |
| Payout Ratio | 36.62% |
| Volume | 54,058 |
| Open | 86.66 |
| Previous Close | 87.02 |
| Day's Range | 86.21 - 86.88 |
| 52-Week Low | 58.97 |
| 52-Week High | 92.30 |
| Beta | 0.53 |
| Holdings | 60 |
| Inception Date | May 1, 2006 |
About IHE
Fund Home PageThe iShares U.S. Pharmaceuticals ETF (IHE) is an exchange-traded fund that is based on the DJ US Select / Pharmaceutical index. The fund tracks a broad-based, cap-weighted index of US pharmaceutical companies. IHE was launched on May 1, 2006 and is issued by BlackRock.
Top 10 Holdings
78.24% of assets| Name | Symbol | Weight |
|---|---|---|
| Johnson & Johnson | JNJ | 23.02% |
| Eli Lilly and Company | LLY | 21.05% |
| Merck & Co., Inc. | MRK | 4.74% |
| Pfizer Inc. | PFE | 4.71% |
| Royalty Pharma plc | RPRX | 4.70% |
| Bristol-Myers Squibb Company | BMY | 4.63% |
| Zoetis Inc. | ZTS | 4.52% |
| Viatris Inc. | VTRS | 4.35% |
| Elanco Animal Health Incorporated | ELAN | 3.32% |
| Jazz Pharmaceuticals plc | JAZZ | 3.21% |
Dividend History
| Ex-Dividend | Amount | Pay Date |
|---|---|---|
| Mar 17, 2026 | $0.28449 | Mar 20, 2026 |
| Dec 16, 2025 | $0.58525 | Dec 19, 2025 |
| Sep 16, 2025 | $0.3124 | Sep 19, 2025 |
| Jun 16, 2025 | $0.30654 | Jun 20, 2025 |
| Mar 18, 2025 | $0.29167 | Mar 21, 2025 |
| Dec 17, 2024 | $0.21082 | Dec 20, 2024 |
Performance
IHE had a total return of 38.73% in the past year, including dividends. Since the fund's inception, the average annual return has been 10.20%.
News
Britain agrees full text of US-UK pharmaceutical trade deal
Britain said on Thursday it had agreed the full text of a U.S.-UK pharmaceutical partnership, setting out terms under which British-made medicines would enter the United States tariff-free.
Why Health Care ETFs Aren't Panicking Over Big Pharma's Price Cuts
As big pharmaceutical companies are set to finalize a deal with the U.S. government to bring down prices for some prescription drugs, another old question is coming into focus for investors: how much ...
Big Pharma Unfazed by Trump Tariffs, But Small Biotechs Face Vulnerability
Drugmakers have been bracing for levies and sought to get ahead of them with pledges to invest billions more on domestic manufacturing.
Trump announces 100% tariffs on pharmaceutical drugs, beginning October 1
President Donald Trump said Thursday that he will put import taxes of 100% on pharmaceutical drugs, 50% on kitchen cabinets and bathroom vanities, 30% on upholstered furniture and 25% on heavy trucks ...
Pharma stocks gain, as Trump's tariff move actually could be a win for the sector
Pharmaceutical stocks mostly gained Friday, as traders appeared to shrug off or even cheer President Donald Trump's rollout of a new tariff plan for drugmakers.
Are Your Health Care ETFs Safe? Trump's New Policies May Trigger Shockwaves Across Pharma Stocks
As the drug industry is in the middle of a growing policy maelstrom in Washington, D.C., investors are closely watching pharmaceutical ETFs to measure market sentiment and ride out the emerging volati...
Trump teases targeted tariffs on overseas drug manufacturers
With the next set of White House–imposed tariffs just hours away from taking effect — including the attention-hogging 104% rate to be levied on products from China as they're imported into the U.S. — ...
Trump Weighs Tariffs on Ireland's Pharma Industry. How to Play the Sector.
Biopharmaceutical stocks are having their time in the spotlight thanks to President Donald Trump, who vowed to take aim at Ireland's status as a pharma hub with new tariffs. Analysts at Jefferies JEF-...
Why investor appetite for commodity funds picked up despite ETF flows broadly seeing ‘pretty big drop' in April
Hello! This week's ETF Wrap digs into the slump in ETF flows in April and investor positioning around commodities as inflation worries persist.
This weight-loss ETF has performed well in its first five months. How does it compare with cheaper alternatives?
A new exchange-traded fund needs an edge to attract investors. This might be its industry focus — a tall order in a crowded market with ETFs covering just about any industry you can imagine.
New ETF invested in Ozempic maker and exposed to other obesity drugs falls in first day of trade
A new ETF hit the market Tuesday, creating buzz for its exposure to popular weight-loss drugs, while expanding the roster of thematic ETFs available for investors willing to pay up for stock-picking p...
Best Pharmaceutical ETFs for Q1 2021
The best pharmaceutical ETFs for Q1 2021 are KURE, XPH, and IHE.